-
Xizhi cGMP Facility
- New Taipei City, Taiwan
- Established in 2019
- 7,800 sq. ft.
- R&D, Pre-Clinical & Pilot-Scale
- Cell and Virus Banking
- Viral Vector Manufacturing Line
- AAV, Lentivirus, Retrovirus and Adenovirus
-
Zhubei cGMP Facility
- Hsinchu County, Taiwan
- To be completed in 2023
- 53,000 sq. ft.
- Late-Stage Clinical & Commercial-Scale
- Cell and Virus Banking
- Manufacturing Multi-suites up to 500L
- Aseptic fill & finish
-
Microbiology QC Lab
- CRO service
- GLP/GMP
- BSL-2
- E.coli bank characterization
- Plasmid release testing
- Sterility/Mycoplasma/Endotoxin
-
Bioanalytical Lab
- CRO service
- GLP/GMP
- BSL-2
- Bank characterization
- Biosafety testing
- Biologics release testing
- Clinical sample analysis
-
Animal Facility
- CRO service
- GLP
- ABSL-2
- Biosafety testing
- Toxicity
- Biodistribution
- Immunogenicity
- Tumorgenicity
-
Kashiwanoha R&D Lab
- Kashiwa, Chiba, Japan
- Established in 2024
- Viral Vector Design
- R&D Grade Production
- Assay and Process Development
- AAV, LV, RV, AdV and Customized
-去背.png){kind=logo}
